Brief: Cassava Sciences Announces Completion Of An Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials
Sept 24 (Reuters) - Cassava Sciences Inc SAVA.O :
* CASSAVA SCIENCES ANNOUNCES COMPLETION OF AN INTERIM SAFETY
REVIEW OF ORAL SIMUFILAM ON-GOING PHASE 3 TRIALS
* CASSAVA SCIENCES INC - DSMB RECOMMENDS CONTINUATION OF
PHASE 3
TRIALS WITHOUT MODIFICATION
* CASSAVA SCIENCES INC - FINAL SAFETY DATA FOR SIMUFILAM
EXPECTED
AT PHASE 3 CONCLUSION
Source text for Eikon: ID:nGNX4pK6xp
Further company coverage: SAVA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing